Understandably, you're likely scratching your head, wondering how it's even possible for a petri dish to play Doom. Good question. The answer is the CL1, "the world’s first code ...

It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...

Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...

Mon, February 16, 2026 at 7:00 PM UTC As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high. Retail sentiment has turned decisively ...

Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S. Now, though, after Lilly stock's ...

Eli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products. Sales from its GLP-1 drugs doubled, and they are key components of the company's business. The stock ...

Eli Lilly 's fourth-quarter results blew past Wall Street estimates on Wednesday, as key GLP-1 drugs, Mounjaro for diabetes and Zepbound to treat obesity, grew triple-digits — and there's still plenty ...

Eli Lilly (LLY) Q4 revenue jumped 43% to $19.3B. Mounjaro sales surged 110% to $7.4B. Novo Nordisk (NVO) expects sales to decline 5% to 13% in 2026 due to pricing pressures and patent losses. Lilly’s ...

Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by comparison. It also has a promising GLP-1 treatment in ...

Strive filed the suit Wednesday in federal court in San Antonio, accusing Lilly and Novo of using their dominance in the GLP‑1 market to prevent patients from getting lower‑priced compounded ...

Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 ...

Forbes contributors publish independent expert analyses and insights. Anisha Sircar is a journalist covering tech, finance and society. This voice experience is generated by AI. Learn more. This voice ...